Evidence map›Paper›PMID 31941916›Full record

ArticleScientific reports2020

SOX9 promotes tumor progression through the axis BMI1-p21

Paula Aldaz, Maddalen Otaegi-Ugartemendia, Ander Saenz-Antoñanzas, Mikel Garcia-Puga, Manuel Moreno-Valladares, Juana M Flores, Daniela Gerovska, Marcos J Arauzo-Bravo, Nicolas Samprón, Ander Matheu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Role of SOX9 protein in ovarian carcinoma: A molecular insight.The Indian journal of medical research · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Deciphering of SOX9 Functions in Pancreatic Cancer Cells.International journal of molecular sciences · 2025
    Article
  8. Review
  9. Implication of protein post translational modifications in gastric cancer.Frontiers in cell and developmental biology · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Paula AldazCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Maddalen Otaegi-UgartemendiaCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Ander Saenz-AntoñanzasCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Mikel Garcia-PugaCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Manuel Moreno-ValladaresCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Juana M FloresDepartment of Animal Medicine and Surgery, Complutense University of Madrid, Madrid, Spain.
Daniela GerovskaComputational Biology and Systems Biomedicine Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Marcos J Arauzo-BravoComputational Biology and Systems Biomedicine Group, Biodonostia Health Research Institute, San Sebastian, Spain.ORCID http://orcid.org/0000-0002-3264-464X
Nicolas SamprónCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Ander MatheuCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain. ander.matheu@biodonostia.org.
Estefania Carrasco-GarciaCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain. estefania.carrasco@biodonostia.org.
Biogipuzkoa Health Research Institute · ESIkerbasque · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The developmental regulator SOX9 is linked to cancer progression mainly as a result of its role in the regulation of cancer stem cells (CSCs). However, its activity in the differentiated cells that constitute the heterogeneous tumor bulk has not been extensively studied. In this work, we addressed this aspect in gastric cancer, glioblastoma and pancreatic adenocarcinoma. SOX9 silencing studies revealed that SOX9 is required for cancer cell survival, proliferation and evasion of senescence in vitro and tumor growth in vivo. Gain of-SOX9 function showed that high levels of SOX9 promote tumor cell proliferation in vitro and in vivo. Mechanistically, the modulation of SOX9 changed the expression of the transcriptional repressor BMI1 in the same direction in the three types of cancer, and the expression of the tumor suppressor p21

Indexed as

AdenocarcinomaCell Line, TumorCell ProliferationCell SurvivalCyclin-Dependent Kinase Inhibitor p21Disease ProgressionGene Expression Regulation, NeoplasticGlioblastomaHumansNeoplasmsNeoplastic ProcessesPancreatic NeoplasmsPolycomb Repressive Complex 1SOX9 Transcription FactorStomach NeoplasmsBMI1 protein, humanCyclin-Dependent Kinase Inhibitor p21Polycomb Repressive Complex 1SOX9 protein, humanSOX9 Transcription Factor

Identifiers

PMID31941916
PMCPMC6962164
OpenAlexW3000564073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.